Fasting-Mimicking Diet Cuts Heart Fat in Type 2 Diabetes Over 12 Months
A randomised trial finds monthly 5-day fasting-mimicking diet cycles significantly reduce myocardial triglyceride content in type 2 diabetes patients.
Summary
A 12-month randomised controlled trial from Leiden University Medical Center tested whether a fasting-mimicking diet (FMD) — five consecutive low-calorie days per month — could reduce fat accumulation in the heart muscle of type 2 diabetes patients. Using cardiac MRI spectroscopy, researchers found the FMD group achieved a significant reduction in myocardial triglyceride content compared to controls receiving usual care alone. This suggests periodic fasting-mimicking cycles may improve cardiac metabolism and potentially lower cardiovascular risk in people with type 2 diabetes, offering a practical dietary intervention that is less demanding than full fasting.
Detailed Summary
Type 2 diabetes dramatically raises cardiovascular risk, and one underappreciated mechanism is myocardial steatosis — the accumulation of triglycerides within heart muscle cells. Excess cardiac fat impairs heart function and contributes to diabetic cardiomyopathy, making it an important therapeutic target beyond blood sugar control.
Researchers at Leiden University Medical Center conducted a 12-month randomised controlled trial enrolling 100 type 2 diabetes patients managed with metformin or no glucose-lowering medication. Participants were assigned to either a fasting-mimicking diet (FMD) program — five consecutive low-calorie days per month alongside usual care — or usual care alone. Myocardial triglyceride content (MTGC) was measured at baseline, 6 months, and 12 months using single-voxel cardiac 1H-Magnetic Resonance Spectroscopy, considered the gold standard for non-invasive cardiac fat quantification.
Of the 100 enrolled, 26 participants (13 per group) had complete imaging data at both baseline and 12 months. The FMD group showed a statistically significant reduction in MTGC of 0.235 percentage points (p=0.027), while the control group showed no significant change (+0.143%, p=0.236). The between-group difference was statistically significant (p=0.018), indicating a genuine dietary effect on cardiac fat metabolism.
These findings suggest that periodic fasting-mimicking cycles can meaningfully alter cardiac lipid metabolism in type 2 diabetes, potentially reducing a key driver of cardiovascular complications. The FMD's appeal lies in its practicality — only five days per month — making sustained adherence more feasible than continuous caloric restriction or full fasting protocols.
Important caveats temper enthusiasm. The imaging subsample was small (n=26), limiting statistical power and generalisability. The full trial mechanism and broader metabolic outcomes are not detailed in this abstract alone. Longer-term and larger studies are needed to confirm whether MTGC reductions translate to hard cardiovascular endpoints.
Key Findings
- Monthly 5-day FMD cycles significantly reduced myocardial triglyceride content by 0.235% over 12 months (p=0.027).
- Control group showed no significant change in cardiac fat (+0.143%, p=0.236) over the same period.
- Between-group difference in MTGC reduction was statistically significant (p=0.018).
- Cardiac fat was measured non-invasively using 1H-Magnetic Resonance Spectroscopy at 3 time points.
- FMD required only 5 consecutive low-calorie days per month, suggesting feasible long-term adherence.
Methodology
12-month randomised controlled trial (NCT03811587) with 100 type 2 diabetes patients on metformin or no medication, split into FMD and usual-care control groups. Myocardial triglyceride content was quantified via single-voxel cardiac 1H-MRS at baseline, 6, and 12 months. Complete imaging data were available for 26 of 100 participants, limiting the imaging analysis sample size.
Study Limitations
The imaging subsample of 26 participants is small, substantially limiting statistical power and the ability to generalise findings. Dropout from MRS assessments introduces potential selection bias. The abstract does not report broader cardiometabolic outcomes, adherence rates, or safety data from the full trial cohort.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.